STAT3 and breast carcinoma: Mu and his team studied the underlying molecular mechanisms, and results showed that glabridin attenuated the angiogenic ability via inhibition of microRNA-520a (miR-520a)-mediated NF-κB/IL-6/STAT-3 signalling, the VEGF secretion, and the angiogenesis in MDA-MB-231 breast cancer cell line [55].